	CDN 1163	Azumolene	RYCAL S107	CGP 37157	Liraglutide
Mitophagy	8.9±12.1% (*p >0.9999)*	**53.0±13.6%** ***(p <0.0001)***	17.8±13.5% (*p 0.9103)*	**102.8±5.1%** ***(p <0.0001)***	12.1±11.6% (*p 0.8878)*
Mitochondrial density	**99.8±23.3%** (***p 0.0061***)	**107.8±14.9%** ***(p <0.0001)***	**62.2±11.8%** (***p 0.0025***)	**137.8±22.8%** (***p <0.0001)***	**136.7±26.4%** (***p 0.0009***)
ATP/ADP ratio	**80.4±7.2%** (***p 0.0001***)	**49.6±9.4%** (***p 0.0004***)	**55.6±8.5%** (***p 0.0001***)	**73.6±9.1%** (***p 0.0001***)	**49.1±10.7%** (***p 0.0197***)
Mitochondrial length	**59.5±10.1%** (***p 0.0001***)	**41.6±11.0%** (***p 0.0155***)	**88.8±11.4%** (***p <0.0001)***	**49.5±11.9%** (***p 0.0116***)	**66.9±10.0%** (***p <0.0001)***
Axonal length	**107.4±21.1%** (***p 0.0017***)	33.3±18.6% (*p* >0.999)	**59.0±13.9%** (***p 0.0023***)	**73.7±16.5%** (***p 0.0008***)	**96.0±24.2%** (***p 0.0038***)

Table 1. Protective effect of different compounds on mitochondrial parameters and axonal development in WFS1 deficient neurons. *P*-values indicate significance level based on One-way ANOVA, Brown-Forsythe ANOVA or Kruskal–Wallis test.